News
![Ardelyx’s-ambition-to-revolutionise-kidney-treatment](https://pharmaphorum.com/wp-content/uploads/2020/12/Ardelyxs-ambition-to-revolutionise-kidney-treatment.jpg)
FDA advisors unconvinced by Reata's kidney disease drug
An FDA advisory committee has delivered a blow to Reata Pharma, after voting unanimously that the drugmaker's data on bardoxolone – a drug for kidney disease – did not show it is effective.